Some of you may have seen the recent news about an experimental drug called brigatinib. This drug is not currently FDA approved, but studies are ongoing and initial results are encouraging. This drug is being studied in patients who have ALK-positive non-small cell lung cancer.
This news highlights the efforts of researchers, patients who enrolled in clinical trials, and the commitment of the FDA to review much needed treatment options for lung cancer.
As Dr. Corey Langer states in the article, treatments may stop working in many patients and it is hoped that brigatinib might “provide patients and their oncologists with a new treatment option.”
More information can be found here: onclive.com/web-exclusives/...